[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611653":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":30,"overallOfficials":11,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":61,"id":65,"slug":11,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients with improved appetite at Week 4 based on the A\u002FCS-12 scale.",null,"Week 4",[14],{"measure":15,"description":11,"timeFrame":16},"Proportion of patients with >5% increase in body weight from baseline at Week 4, Week 8, and Week 12.","Proportion of patients with >5% increase in body weight from baseline to week 12.",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"NA","SINGLE_GROUP","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24],{"label":25,"type":26,"description":27,"interventionNames":28},"Nanocrystalline Megestrol Acetate Oral Suspension + Standard Antitumor Therapy","EXPERIMENTAL","This cohort focuses on patients who have already been diagnosed with cachexia before the initiation of this study and are scheduled to receive treatment with nanocrystalline megestrol acetate.",[29],"Drug: Nanocrystalline Megestrol Acetate",[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"DRUG","Nanocrystalline Megestrol Acetate","Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg\u002FmL, administered orally at a dose of 5 mL per day (625 mg\u002Fday), and the primary endpoint efficacy collection will be conducted in the 4th week.",[25],[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Suxia Luo","CONTACT","18638553211","luosxrm@163.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Henan Cancer Hospital, Affiliated to Zhengzhou University","RECRUITING","Zhengzhou","Henan","45000","China","CN",{"type":52,"coordinates":53},"Point",[54,55],113.64861,34.75778,{"lat":55,"lon":54},[58],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[62],{"name":63,"class":64},"Henan Cancer Hospital","OTHER_GOV","100611653",false,"NCT07243379","A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia","Inclusion Criteria:\n\n* Patients with histologically and\u002For cytologically confirmed malignancy.\n* Age ≥18 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and an expected survival of ≥3 months.\n* Meeting the diagnostic criteria for cachexia (based on Fearon's criteria).\n* Body mass index (BMI) ≤30.\n\nExclusion Criteria:\n\n* Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting; patients receiving tube feeding or parenteral nutrition.\n* Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.\n* Patients with acquired immunodeficiency syndrome (AIDS).\n* Currently receiving or planning to receive other medications that increase appetite or body weight, such as corticosteroids (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.\n* Patients with Cushing's syndrome, adrenal or pituitary insufficiency, or poorly controlled diabetes mellitus.","ALL","18 Years","85 Years",{"count":74,"type":75},495,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.",[81,82],"Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia","Multicenter Observational Study","2025-11-19",{"date":85,"type":86},"2025-11-21","ACTUAL",{"date":88,"type":86},"2025-09-25",{"date":90,"type":75},"2027-06-30",{"name":5,"class":6},1]